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ABSTRACT

Cisplatin Analogues Containing 4,4'-Bis[alkyl]-2,2'-bipyridine Derivatives
by
Zeynep Gizem Kabuloglu Karayusuf
Dr. Vernon Hodge, Examination Committee Chair
Professor of Chemistry
University of Nevada, Las Vegas
Cisplatin is used clinically to treat various types of cancer. While effective in
treating a variety of cancers it exhibits a wide range of side effects. Synthesis of
novel cisplatin analogs, which exhibit increased cytotoxicity at lower doses, may
alleviate some of the side effects.
These analogs utilize 4,4'-bis(alkyl)-2,2'-bipyridine, a diimine, in place of the
ammonia ligands present in cisplatin and the addition of substituents to the 4,4'position as well as coordination to PtCl2 to yield a series of (4,4'-bis[alkyl]-2,2'bipyridine) PtCb compounds. Modifications at the 4,4'-position occur by
generating a benzylic dianion by way of lithium diisopropyl amide (LDA) and then
substituting with the desired alkyl halide in a S n 2 reaction. The different
substitutions made in the 4,4' position are as follows: ethyl, propyl, n-butyl,
methoxy and 3-methoxy-n-propyl. All of the coordination reactions have been
done by ligand exchange where by PtCb exchanges from 1,5-cyclooctadiene
(COD) to the bipyridine ligand.
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ABBREVIATIONS

Abbreviation

Definition

AAG

3-methyladenine DNA glycosylase

bipy

2

n-BuLi

n-butyllithium

Cisplatin

c/s-diamminedichloroplatinum (II)

CDCI3

deuterated chloroform

COD

1,5-cyclooctadiene

C0D-PtCl2

1,5-cyclooctadiene platinum (II) dichloride

DMSO

dimethyl sulfoxide

DMSO-de

deuterated dimethyl sulfoxide

DNA

deoxyribonucleic add

DNA-PK

deoxyribonucleic acid protein kinase

EC 50

effective concentration (50%)

G

guanine

G2

gap

GG

guanine-guanine

GC/MS

gas chromatography/ mass spectroscopy

HBV

hepatitis B virus

HeLa

human cervix carcinoma

,2 '-bipyridine

2

phase of cell cycle

VI
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HMG

high mobility group proteins

His

histidine

HMG

high mobility group proteins

HPV

human papiloma virus

LDA

lithium diisopropyl amide

Met

methionine

MMR

mismatch repair

NER

nucleotide excision repair

NMR

nuclear magnetic resosnance

K2 Cr2 0 y

potassium dichromate

K2PtCl4

potassium tetrachloroplatinate (II)

Pd/C

palladium over carbon

ppm

parts per million

ppt

precipitate

PPTS

pyridinium p-toluene sulfonate

RBF

round-bottomed flask

RNA

ribonucleic acid

SSRP1

structure-specific recognition protein

TBP

TATA-binding protein

THF

tetrahydrofuran
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CHAPTER 1

INTRODUCTION
Cisplatin is used clinically to treat various types of cancer. While effective in
treating testicular, ovarian, head and neck tumors, it exhibits side effects
including “nephrotoxicity, neurotoxicity and ototoxicity” [1]. The objective of the
project was to synthesize novel cisplatin analogs that rhay exhibit increased
cytotoxicity at lower doses and alleviate some of the side effects. These analogs
utilized

2

,2 '-bipyridine, a diimine, in place of the ammonia ligands present in

cisplatin. Further modifications included the addition of substituents to the 4,4'position. Over the course of the investigation, we have generated a few novel
4,4'-disubstituted-2,2'-bipyridine compounds as part of a homologous series of
cisplatin analogues as well as made improvements to synthetic procedures of
previously synthesized compounds.
According to the American Cancer society it is expected that in this year
alone 1,444, 920 new cases of cancer will be diagnosed [2]. Cancer is one of the
most complicated and idiosyncratic group of diseases fought by modern
medicine today. Cancer is often characterized by uncontrolled growth and motility
of abnormal cells, which cause problems in vital organs, circulatory and other
systems. Various factors are causative agents of these diseases and these
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factors act either singly or synergistically. However, it is not known specifically
what the actual causative agents of cancer are from patient to patient. External or
environmental factors include exposure to carcinogenic and mutagenic chemicals
such as tobacco smoke, solvents etc., radiation exposure, such as UV rays and
exposure to infectious organisms such as Hepatitis B Virus (HBV) and Human
Papiloma Virus (HPV) [2]. Internal factors are often inherited mutations, which
can exhibit problems in hormonal, immune and in general metabolic systems [2 ].
Various methods exist for treating cancer such as chemotherapy, radiation and
surgery. These therapies can be used individually or concomitantly [2]. Cisplatin
is a commonly used chemotherapy drug.

1.1 A Brief History of Cisplatin
In 1845, Michael Peyrone synthesiszed cis-diamminedlchloroplatinum (II),
then called Peyrone s chloride, currently known as cisplatin. The structure of this
compound was not elucidated until 1893 by Alfred Werner [3]. (See Figure 1) In
1965, Rosenberg and his team discovered, quite by accident, when using a
platinum electrode, there was inhibition of cell division in Escherichia co//grown
in ammonium chloride media. Later the compound causing this inhibition was
found to be cisplatin [4]. Afterward, Rosenberg and his team isolated and tested
this compound on sarcoma 180 and leukaemia L I 210 in mice and found the
compound to be a potential new class of anti-tumour agents [5]. In 1971, cisplatin
entered clinical trials, and in 1977 was marketed exclusively by Bristol-Myers
Squibb, under the brand name Platinol [3.] By 1985 approximately 2000 analogs
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of cisplatin and cisplatin-related compounds had been investigated [6 ] in an effort
to ameliorate the high toxicity exhibited by cisplatin. Nephrotoxicity in cisplatin is
dose limiting, [7], however hydration therapy diminishes dramatically the toxicity
allowing the increase of the dose up to 3 times [8 ].

NH 3 .N H 3
Pt
Cl
01

O
NH

O

Figure 1. Cisplatin, Carboplatin and Oxaliplatin, respectively.

1.2 Mechanism of Action of Cisplatin
The exact mechanism by which cisplatin is able to execute its cytotoxicity is
not well known. High levels of chlorides are found in extracellular and
extranuclear fluids allowing cisplatin to remain in its stable, nonreactive dichloro
form [9]. Within the cellular membranes the concentration of chloride drops
dramatically from approx 1.5M to approx 4mM, thus kinetic activation of cisplatin
is rendered once it crosses the cell membrane and it exchanges its chlorides for
water yielding a more reactive monoaqua and diaqua species [ 1 0 ].

c/s-Pt(NH3)2Cl2 (H20)->c/s[Pt(NH3)2CI(H20)]^ + Cr^c/s[Pt(NH3)2Cl(H20)2]^^ + Cr
Cisplatin binds in a 1,2-G,G-intrastrand and G,C-interstrand adduct crosslinks
with DNA (see Figure 2), specifically binding to N7 atoms of guanine residues in
the same or opposite strands, correspondingly [11,12]. With the formation of the
1,2-G,G-intrastrand adducts important modifications are made to the topological
structure of DNA which becomes bent or kinked [13, 14]. It is believed at this
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point the HMG (High Mobility Group) proteins recognize the adduct formed
[15,16] and DNA repair mechanisms are triggered. The nucleotide excision repair
(NER) system seems to be the main system for repair of damage caused by
cisplatin [17,18,19,20]. Mismatch Repair (MMR) system recognizes 1,2-G,Gintrastrand adduct, via hMutS-a, but does not remove the adduct or is incapable
of doing so, thus inducing signaling to an apoptotic pathway [21,22]. It has been
reported that the cisplatin-DNA adduct has the capability to inhibit the kinase
activity of DNA-PK protein, a repair protein, by binding to the Ku subunit of DNAPK [23]. The HMG DNA-binding moiety is found in structure-specific recognition
protein 1 (SSRP1) has a high specificity recognition for 1,2-G,G-intrastrand
adducts [24] reinforcing the unknown but highly speculated hypothesis that the
1,2-G,G-intrastrand adduct cross-links are the major adducts formed in the action
mechanism of cisplatin [25].

NHj

NH

NHz
OH----NH
--P t
NH;

O
Figure 2. 1,2-G,G-lntrastrand Adduct.
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Two mechanisms of action via HMG proteins have been postulated: The
“repair shielding model” proposes that the protection of adducts by HMG proteins
could be affecting recognition, by DNA repairing enzymes [26] and the “hijacking
model” implies triggering of cell cycle events leading to cell death by SSRP1
and/or other HMG proteins [27]. Besides the HMG-domain family of proteins,
other proteins such as TATA-Binding Protein (TBP) and 3-methyladenine DNA
glycosylase (AAG) seem to recognize the cisplatin-DNA adduct [28,29]. Cisplatin
degrades and shortens telomeres suggesting yet another mechanism of cell
death in HeLa (human cervix carcinoma) cells [30]. G 2 phase cell cycle arrest
induced by cisplatin-adducts apparently indicates inhibition of transcription by
RNA Polymerase II and its consequent degradation by ubiquitination [31]. A
more direct interaction with ubiquitin may engender a different cytotoxic
response, cisplatin binds to ubiquitin protein in two sites: M etl and His 6 8 , and 4
types of adducts are known to be formed [32]. A direct relationship has not yet
been established between p53-mediated response to cisplatin induced cell
damage, for each cell type and cell environment there seems to be an
idiosyncratic response [33]. All the previously mentioned mechanisms could work
individually or concomitantly, or could be part of the same cascade of events or
related to yet unknown events, it is not known how they relate to each other
based on cisplatin adduct formation and induced damage. [31]

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

1.3 A Brief History of 2,2'-Bipyridine
2,2'-bipyridine was first synthesized by Fritz Blau in 1888 via dry-distillation of
picolinic acid copper salt [32]. The first synthesis of substituted 2,2'-bipyridines
was carried out by Case in 1946 utilizing an Ullman reaction with a copper metal
catalyst [33]. From that point on the popularity of bipyridines as a building block
has increased dramatically, many preparation improvements have been made
and its use in various subfields of chemistry, predominantly as a metal chelating
agent in coordinate systems, has found numerous applications in: analytical
chemistry [34], electrochemistry [35], polymer chemistry [36], photonics and
optoelectronics [37] and more recently although less thoroughly investigated in
biochemistry (see section 1.4 for more detail and references).

2'

2

4

Figure 3. 2,2'-Bipyridine with Ring Numbering Scheme.
Symmetric substitution synthesis in the 3,3', 4,4', 5,5',

6

,6 ' positions of the

2,2'-bipyridine has been thoroughly researched [38], however there seems to be
a need for more efficient synthetic systems to be designed as will be discussed in
the results section. Our primary research focus is on the 4,4' position
substitution of 2,2'-bipyridine system. Many 4,4'-disubstituted-2,2'-bipyridines
where synthesized by utilizing similar classic organic reactions, such as nitration,
for the introduction of substituents into the conjugated rings [33, 39].
Consideration must be given to the fact that the 2,2'-bipyridyl moiety has a
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tendency to form A/,A/-dioxide (or 1,1'-dioxide) occurring after an oxidation
reaction, and must be reduced [39]. 4,4'-Bis(methyl)-2,2'-bipyridine was
synthesized utilizing 2-bromo-4-methylpyridine heated with copper powder to 220
°C [33]. 4,4'-Bis(ethyl)-2,2'-bipyridine was first synthesized by utilizing 4ethylpyridine by refluxing with degassed Raney Ni as the catalyst, to generate a
heterocyclic biaryl [40]. 4,4'-Bis(n-butyl)-2,2'-bipyridine was first synthesized
utilizing 4-n-butylpyridine catalyzed by Pd/C [41]. 4,4'-Bis(m ethoxy)-2,2'bipyridine was fist synthesized from 4,4'-Bis(nitro)-2,2'-bipyridine and sodium
methoxide yielding 4,4'-bis(methoxy)-2,2'-bipyridine-1,1 '-dioxide and reduced by
phosphorous trichloride in chloroform [39].

1.4 Generation of Novel Compounds as Cisplatin Analogues
Various reasons generate a demand for novel pharmaceutical compounds,
specially in cancer pharmacology, for example: side-effects that are extremely
taxing to patients, inactivity or drug-resistance from one cancer-type to the next
and differences in response to drug, from patient to patient. Despite the large
number of compounds related to cisplatin that have been synthesized over the
years, only two related anti-cancer compounds, besides cisplatin, have been
FDA approved, carboplatin and oxaliplatin [42]. (see Figure 1)
Before considering what to synthesize as an analogous compound, one must
look at the structure and properties that incite such activity. General structureactivity relationships for cisplatin-related compounds have the following
properties:

1

) complexes should be electrically neutral,

2

) one bidentate or two

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

monodentate structure with cis conformation are the requirement for the non
exchanging ligand as well as the exchanging or leaving groups, 3) leaving groups
should not be too stable or too strongly reactive, 4) the non-exchanging ligand
should be firmly bonded and be a strongly donating group such as a primary or
secondary amine [43].
The 2,2'-bipyridine structure is considered a bidentate ligand in which its
nitrogen atoms bind, in a coordinate manner, to metals, in this case specifically
platinum. By binding the bipyridine ligand to Pt (II), a structural moiety similar to
that of cisplatin is achieved. Both cisplatin and a Pt (II) coordinated 2,2'bipyridine molecules are square planar [44], hypothetically rendering both similar
functionality and binding.
It has been demonstrated that the 2,2'-bipyridyl Pt (II) complex can
intercalate DNA [45]. Whether this intercalation is similar to the binding of
cisplatin to DNA is not known and has not yet been explored. Garelli et al. have
synthesized a series of 4,4'-perfluoroalkyl-2,2'-bipyridine ligands complexed to
Pt (II) incorporated into liposomes and tested these compounds for cytotoxic
activity in CAL 27 cell line. [46,47,48]. These compounds show cell growth
inhibition but in a lesser magnitude than cisplatin [48]. In another study, 3,3 disubstituted-2,2'-bipyridines ligands complexed to Pt (II) were synthesized and
tested for their activity in leukemia L1210 cell line, and showed no anti-tumor
activity[49]. It must be considered that the 3,3' substituted position has a noncoplanar conformation due to steric hindrance [38] and this may be the reason
for its lack of cytotoxic activity. Another study dealing with a similar structure of a

8
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2,2'-bipyridine ligated to Pt(ll) and 1,1-cyclobutanedicarboxylic acid as the anion
demonstrated lesser cytotoxic activity than cisplatin in Pass lymphocytic leukemia
cells [50]. Elwell et al. demonstrated that [4,4'-Bis(4,4,4-trifluorobutyl)-2,2'bipyridine] PtCb and [4,4'-Bis(methyl)-2,2'-bipyridine] PtCb exhibited a higher
cytotoxicity than that of cisplatin, from 14 to 125 fold depending on the compound
and the cell line [51, 52]. Based on these results, it was decided to synthesize a
homologous series of [4,4'-Bis(alkyl)-2,2'-bipyridine] PtClz, of increasing chain
size in the 4,4' position for the specific purpose of future testing in various cell
lines and in order to produce some type of structure-activity relationship specific
to these compounds and how these particular substituents in the 4,4' position
affect biochemical activity and perhaps determine the mechanism of action within
the cell.
In the following investigation, 4,4'-bis(methyl)-2,2'-bipyridine was used as the
starting material for the synthesis of the 4 , 4 -bis(alkyl)-2,2 -bipyridines. A typical
procedure involved generating a dianion species at the benzyl position, utilizing
lithium diisopropylamide (LDA) as the strong base to remove the methyl protons,
and a consequent Sn^ reaction with an alkyl halide afforded the modifications to
the ligand [46, 51, 53]. Then a ligand exchange reaction between 1,5cyclooctadiene-PtCl2 (C 0 D-PtCl2 ) and the 4,4'-Bis(substituted)-2,2'-bipyridine
ligand was executed, yielding the final Pt (II) coordinated bipyridine [51,54].
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CHAPTER 2

MATERIALS AND METHODS
2.1. Materials
The following chemicals were purchased from Alfa Aesar; 2,2'-bipyridine,
4,4'-dimethyl-2,2'-bipyridine, 2.5 and 2.9 M n-BuLi (in hexanes), diisopropyl
amine, iodomethane, iodoethane,

2

-bromoethyl methyl ether,

2

-( 2 -

bromoethoxy) tetrahydro-2H-pyran, 2-(2-Bromoepropoxy) tetrahydro-2H-pyran,
PPTS and acetone-de with 1% TMS. 4 , 4 -dimethoxy-2,2 -bipyridine, 4,4 dialdehyde- 2 ,2 '-bipyridine, 1,5-cyclooctadiene SnCb and DMSO-de with

0

.1 %

TMS were purchased from Aldrich. K2 PtCl4 , CDCI3 with 0.03% TMS and
K 2 Cr2 0 7 , were purchased from Acros. n-Propyl iodide was obtained from TCI
America. . 4,4’-diamine-2,2’-bipyridine was purchased from Carbosynth Limited,
UK. All materials purchased were above 95% purity and were used without
further purification unless noted in the procedure.

2.2. Spectroscopy and Analytical Methods.
NMR spectra were obtained utilizing Varian 400 MHz VnmrJ 2.1 A (Palo Alto,
CA.) ’’H, 400 MHz and ^^C, 100 MHz spectra were obtained utilizing the
following deuterated solventsiCDCIa, DMSO-de and acetone-de, all of which

10
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contain TMS and were used for reference peaks. GC/MS spectra were obtained
utilizing Varian 4000 GC/MS/MS (Palo Alto, CA.) Elemental Analysis was
provided by Desert Analytics, Tucson, AZ, USA and by Dr. S. Steinberg in the
UNLV Chemistry department utilizing an Exeter CE 440 (UK)

2.3 Synthetic Methods
General note for synthetic methods: all reactions substituting the 4,4' position
in the bipyridine that utilized the strong base lithium diisopropylamide (LDA) were
carried out under inert atmosphere, N2 or Ar. This atmosphere was exchanged
utilizing a Schlenk line gas and vacuum set up. All transfers were done via
purged syringes and canulas. The solvent utilized in these reactions was
anhydrous THF and it was directly used without further drying. All glassware was
cleaned and dried in an oven and purged before use.
2.3.1. Preparation of COD-PtC^, 1
A 500 mL round-bottomed flask (RBF) was charged with 2.5 g (6.0 mmol) of
K2 PtCl4 , exchanged atmosphere to N2 using a vacuum Schlenk line, and 40 mL
of distilled H2 O was added to the flask. Then on a 50 mL RBF, 27.5 mL of npropanol, 5 mL of 1,5-cyclooctadiene (COD) and 37.5 mg of SnCl2 were
combined and allowed to dissolve. After dissolving, the solution was added to the
500 mL RBF and stirred at room temperature under N2 for 94 hrs. The crude
product was filtered through a coarse fritted funnel and washed with ethanol and
distilled H2 O and afterward allowed to air dry. The washed solid was weighed

11
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yielding 2.107g (5.63 mmol) (94% yield) in the form of a white powder, which was
used without further purification [54].
2.3.2. Preparation of (2,2'-bipyridine) PtCl2 , 2
A 100 ml RBF was charged with 0.150 g (0.960 mmol) of 2,2'-bipyridine and
0.359 g (0.960 mmol) of COD-PtCb along with 20 mL of acetonitrile. The RBF
was set-up with a condenser and in an oil bath to reflux at 95 °C for 24 hrs. The
RBF was cooled, all solvent was evaporated to dryness, then additional
acetonitrile was added to the crude product and filtered onto a fritted filter. The
solid was washed with copious amounts of water, and allowed to air dry. The dry
solid weighed 0.3528g (0.836 mmol) (87% yield) and was in the form of a bright
yellow powder, m.p. >380 °C (decomposition).
2.3.3.A. Preparation of 4,4'-bis[ethyl]-2,2'-bipyridine, 3
A 3-neck 250 ml RBF, with a drip funnel attached, was charged with a stir bar
and 1.54 mL (11 mmol) of diisopropyl amine and 20 mL of THF was added via
syringe under an argon atmosphere at 0 °C in a brine bath. Then 4.4 mL (11
mmol) of n-BuLi (2.5 M) was added, via syringe, drip wise to the same flask. A 50
ml RBF was charged with 0.920 g (5 mmol) of 4 ,4'-dimethyl-2,2'-bipyridine,
degassed with a vacuum and dissolved in 30 mL of anhydrous THF and
transferred to the drip funnel. The dissolved bipyridyl was dripped slowly onto the
lithium diisopropylamide (LDA) to produce a dark red colored anion. After 10
min, 0.68 mL (11 mmol) of iodomethane was added to the 3-necked RBF via
syringe. The solution was stirred for 24 hrs and allowed to warm to room
temperature. The reaction was under an argon atmosphere at all times. After 24

12
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hrs, the product had a yellow oily appearance. This crude product was extracted
with water and diethyl ether, and dried with Na2 S 0

4

. The final product was

isolated 0.9137g (4.309 mmol) (8 6 % yield) in the form of a yellow oily liquid.
2.3.3.B. Preparation of (4,4'-bis[ethyl]-2,2'-bipyridine) PtCl2 , 4
Coupling of compound 3 to C 0 D-PtCl2 , 1, was carried out in the following
manner. A 100 mL RBF was charged with 0.212 g (1.0 mmol) of compound 3
and 0.374 g (1.0 mmol) of COD-PtC^and 10 mL of acetonitrile, set up with a
condenser and allowed to reflux for 24 hrs in an oil bath at 95 °C. The RBF
containing the mixture was cooled to room temperature. The solvent was
removed by rotary evaporation. The resulting precipitate was washed in
acetonitrile and filtered through a fritted funnel. The final product was weighed
0.3483g (0.729 mmol) (73% yield) in the form of a bright yellow powder, m.p.
368-370 °C.
2.3.4.A. Preparation of 4,4'-bis[propyl]-2,2'-bipyridine, 5
A 3-necked 250 ml RBF, with a drip funnel attached, was charged with stir bar
and 1.54 mL (11 mmol) of diisopropyl amine and 20 mL of THF under an argon
atmosphere at 0 °C in a brine bath. Then 3.79 mL (11 mmol) of n-BuLi (2.9 M)
was added drop wise to the same flask. A 50 ml RBF was charged with 0.920 g
(5 mmol) of 4,4'-dimethyl-2,2'-bipyridine, degassed under a vacuum and
dissolved in 30 mL of anhydrous THF and transferred to the drip funnel. The
dissolved bipyridyl was dripped slowly onto the LDA to produce a dark red
colored anion. After 10 min, 0.88 mL (11 mmol) of iodoethane was added to the
3-neck RBF via syringe. The solution was stirred for 24 hrs and allowed to warm
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to room temperature. The reaction was under an argon atmosphere at all times.
After 24hrs, the product has yellow oily appearance. This crude product was
extracted with water and diethyl ether, and dried with Na2 S 0

4

. The crude

product gave a mixture of two compounds monosubstituted (1/3 of total product)
and disubstituted (2/3 of total product). This is discussed in more depth in the
results and discussion section. Due to this mixture, silica gel column
chromatography was used for separation of products, with ethyl acetate as the
eluent. The final product was isolated 0.800 g (3.3mmol) (6 6 % yield) in the form
of a yellow oily liquid.
2.3.4.B. Preparation of (4,4'-bis[propyl]-2,2'-bipyridine) PtCb,

6

Coupling of compound 5 to COD-PtCb, 1, was carried out in the following
manner. A 100 mL RBF was charged with 0.127 g (0.529 mmol) of compound 5
and 0.1979 g (0.529 mmol) of C 0 D-PtCl2 and 10 mL of acetonitrile, set up with a
condenser and allowed to reflux for 24 hrs in an oil bath at 95 °C. The RBF
containing the mixture was cooled to room temperature. The solvent was
removed by rotary evaporation. The resulting precipitate was washed in
acetonitrile, filtered through a fritted funnel and allowed to air dry. The final
product was isolated 0.1869 (0.369 mmol) (70% yield) in the form of a bright
yellow powder, m.p. 214-216 °C.
2.3.5.A. Preparation of 4,4'-bis[n-butyl]-2,2'-bipyridine, 7
A 250 ml 3-neck RBF, with a drip funnel attached, was charged with stir bar
and 1.75 mL (12.5 mmol) of diisopropyl amine and 20 mL of THF under a N2
atmosphere at 0 °C in a brine bath. Then 4.8 mL (12.5 mmol) of n-BuLi (2.6 M)
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was added drip wise to the same flask. A 50 ml RBF was charged with 0.920 g
(5mmol) of 4,4'-dimethyl-2,2'-bipyridine, degassed under a vacuum and
dissolved in 30 mL of anhydrous THF and transferred to the drip funnel. The
dissolved bipyridyl was dripped slowly onto the LDA to produce a dark red
colored anion. After 10 min, 1.21 mL of n-propyl iodide, that was passed through
a mini pipette silica column, was added to the 3-neck RBF. The solution was
stirred for 24 hrs and allowed to warm to room temperature. The reaction was
under a N2 atmosphere at all times. After 24hrs, the product had a yellow oily
appearance. This crude product was extracted with water and diethyl ether, and
separated through a silica column using ethyl acetate. The final product was
isolated 0.9751 g (3.638 mmol) (73% yield) in the form of a yellow oil [55].
2.3.5.B. Preparation of (4,4'-Bis[n-butyl]-2,2'-bipyridine) PtCb,

8

Coupling of compound 7 to COD-PtCb, 1, was carried out in the following
manner. A 100 mL RBF was charged with 0.1151 g (0.429 mmol) of 1 and
0.1607 g (0.429 mmol) of C 0 D-PtCl2 and 10 mL of acetonitrile, set up with a
condenser and allowed to reflux for 24 hrs in an oil bath at 95 °C. The RBF
containing the mixture was cooled to room temperature. The solvent was
removed by rotary evaporation. The resulting precipitate was washed in
acetonitrile and filtered through a fritted funnel. The final product was weighed
0.1743g (0.3262 mmol) (76% yield) in the form of a bright yellow powder, m.p.
215-218 °C.
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2.3.6. Preparation of (4,4'-bis[methoxy]-2,2'-blpyrldlne) PtCl2 , 9
In a 100 ml RBF was charged with 0.216 g (1.0 mmol) of 4,4'-dim ethoxy-2,2'bipyridine and 0.374 g (1.0 mmol) of C0D-PtCI2 along with 20 mL of acetonitrile.
The RBF was set-up with a condenser and in an oil bath to reflux at 95 °C for 24
hrs. The RBF was cooled, all solvent was evaporated to dryness, then
acetonitrile was added to the crude product and filtered in to a fritted filter. The
solid was washed with copious amounts of water and allowed to air dry. The final
solid was weighed 0.3075g (0.6377 mmol) (64% yield) in the form of a bright
yellow powder, m.p. 318-320 °C.
2.3.7.A. Preparation of 4,4'-bis[3-methoxy-n-propyl]-2,2'-bipyridine, 10
The same method for preparing compound 3 applies. The only difference was
4 equivalence of 2-Bromo-ethyl methyl ether was added. If not used in excess,
this substituents gives part monosubstituted (10 % of total yield) and part
disubstituted (90 % of total yield) products based on possible side reactions and
elimination in a strong base. The product was extracted and purified same as
compound 3. The final product was isolated 0.5229g (1.743 mmol) (35 % yield) in
the form of a white crystal, m.p. 38-40 °C.
2.3.7.B. Preparation of (4,4'-bis[3-methoxy-n-propyl]-2,2'-bipyridine) PtCIa, 11
Compound 11 was synthesized in the same manner as was compound 2
utilizing 0.1059 g (0.353 mmol) of 4,4'-bis[n-butyl-4-methoxy]-2,2'-bipyridine and
0.1321 g (0.353 mmol) of COD-PtCb. The final product was weighed 0.1738g
(0.307 mmol) (87% yield) in the form of a bright yellow powder, m .p.177-180 °C.
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2.4 Structures and Synthetic Schemes

1)2eq. LDA in THF 0 °C
2) 2 eq. Alkyl halide

Alkyl Halides Used
CH3I

3
5
7

CH3 CH2 I
CH3 CH2 CH2 I
CH3 0 CH2CH2Br

R=-CH2CH3
R—-CH2CH2CH3
R=-CH2CH2CH2CH3

10 R--CH2CH2CH20CH3

Figure 4. Synthetic scheme for 4,4'-Bis(substituted)-2,2'-bipyridine ligands.

COD-Pt
CH3 CN reflux at 95 °C
C l'

2
4
3
5
7

'ci

R=-H
R—-CH2 CH3

6 R=-CH2CH2CH3

R=-CH2CH3
R=-CH2CH2CH3
R=-CH2CH2CH2CH3

8

R=-CH2CH2CH2CH3

9

R=-0CH3

11 R=-CH2CH2CH20CH3

10 R=-CH2CH2CH20CH3

Figure 5. Synthetic scheme for [4,4'-Bis(substituted)-2,2'-bipyridine] PtClg.
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y \
11

10

Figure 6. Structures of Compounds.
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2.5 Attempted Synthesis of 7 Compounds.
2.5.1 Attempted synthesis of 4,4'-bis[hydroxy]-2,2’-bipyridine, I
The synthesis of compound I from 4,4'-bis[methoxy]-2,2’-bipyridine was
executed via ether cleavage reaction utilizing HBr and glacial acetic acid [56].
However this reaction did not yield a single product and was difficult to isolate.
2.5.2 Attempted synthesis of 4,4'-bis[hydroxymethyll]-2,2’-bipyridine, II
The synthesis of compound II from 4,4'-bis[methyl]-2,2'-bipyridine was
carried out by first oxidizing with K2Cr20/, this product was isolated yielding 4,4'bis[carboxy]-2,2'-bipyridine. The acid was reacted with

H 2S O 4

and

C H 3 O H

to

give 4,4'-bis[methoxycarbonyl]-2,2'-bipyridine which was also isolated, then it
was reduced with LiAIH 4 and did not yield product. It was also consequently
reduced with NaBH 4 and did not yield the desired product either, regardless of
following the literature step by step [57,58].
2.5.3 Attempted synthesis of 4,4'-bis[hydroxypropyl]-2,2’-bipyridine, III
The synthesis of III from 4,4'-bis[methyl]-2,2'-bipyridine was carried out as in
reaction of compound 3 utilizing 2-(2-bromoethoxy) tetrahydro-2H-pyran yielding
a mono and disubstituted product, which was difficult to isolate via column
chromatography [59,60].
2.5.4 Attempted synthesis of 4,4'-bis[hydroxy-n-butyl]-2,2’-bipyridine, IV
The synthesis of IV from 4,4'-bis[methyl]-2,2'-bipyridine was carried out as in
reaction of compound 3 utilizing 2-(2-bromopropoxy) tetrahydro-2H-pyran
yielding a mono and disubstituted product, which was difficult to isolate via
column chromatography. [59,60,61]
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2.5.5 Attempted synthesis of (4,4'-bis[formyi]-2,2'-bipyridine) PtC^, V
The synthesis of V from 4,4'-bis[formyl]-2,2'-bipyridine was carried out with
similar methodology as in compound 2. In this reaction there were two products
that were not isolable one was yellow and another green. This is the first instance
of synthesis of this compound. The yellow product is believed to be the desired
product, the green one seems to have a similar arrangement such as a Magnus’
salt [62], however this has not been concretely established.
2.5.6 Attempted synthesis of (4,4'-bis[carboxy]-2,2'-bipyridine) PtCb, VI
The synthesis of VI from 4,4'-bis[carboxy]-2,2'-bipyridine was carried out with
similar methodology as in compound 2 but did not yield the desired product. This
is the first instance of synthesizing this compound via this methodology.
2.5.7 Attempted synthesis of (4,4'-bis[amine]-2,2'-bipyridine) PtCb, VII
The synthesis of VII from 4,4'-bis[amine]-2,2'-bipyridine was carried out with
similar methodology as in compound 2. This reaction gave the desired product
confirmed by

NMR, however the elemental analysis shows a higher

percentage for C and H. Analytical Calculated: C 26.56 %, H 2.23 %, N 12.39 %.
Experimental: C 32.40 %, H 3.16 %, N 11.32 %. The yellow solid seems to be
the correct product but it is contaminated with COD.
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'O H

HO'

, x
VI

VII

IV
Figure 7. Attempted Synthesis of 7 Compounds.
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CHAPTER 3

RESULTS
The following contains the analytical and spectroscopic characterization
results of the products synthesized by the reactions described in the Materials
and Methods section. (See Appendix for ’’h, ^^C NMR and GC/MS spectra.)
3.1. (2,2'-Bipyridine) PtClz, 2
Analytical Calculated for CioH 8 Cl2 N2 Pt: C 28.45 %, H 1.91 %, N 6.64 %.
Experimental: C 28.49 %, H 1.77 %, N 6.42 %.
NMR:

(400 MHz, 298.1 K, DMSO-de) § 9.514, (d, J=4.00 Hz, 2H, Ar-H

6,6'), 8.599, (d, J=7.60 Hz, Ar-H 3,3 ) 8.440, (m, 2H, Ar-H 4,4'), 7.864 (m, 2H,
Ar-H 5,5 ).
NMR: ^^C {^H} (100 MHz, 298.1 K, DMSO-de) 8 157.505 (2C, 2,2 ) 149.074
(2C,6/6 ) 141.216 (2C, 3/3 ) 128.395 (2C, 4/4') 124.868 (2C, 5/5 )
The synthesis for compound 2 has been previously executed [63] by K2 PtCU
in HCI and refluxing, however this is the first instance of synthesis utilizing CODPtCl2 and the methodology mentioned in the previous synthesis section.
3.2.A. 4,4'-Bis[ethyl]-2,2'-bipyridine, 3
MS (El: 70 eV, m/z) 211 {M '\ 100%), 196 (M^ -CH 3 . 15.2%) 184 (M^ -CH 3 ,
21.25%) 169 (M" -CH 2 , 12.5%)

22

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Compound 3 has previously been synthesized [40]. However, this is the first
synthesis of this compound utilizing 4,4'-Bis(methyl)-2,2'-bipyridine as the
starting material.
3.2.B. (4,4'-Bis[ethyl]-2,2'-bipyridine) PtCIa, 4
Analytical Calculated for C i 4 HieCl2 N2 Pt: C 35.16 %, H 3.37 %, N 5.86 %.
Experimental: C 34.81 %, H3.41 %, N 5.86 %.
NMR: ■'H (400 MHz, 298.1 K, DMSO-dg) Ô 9.279, (d,

^ J h h = 6 .0 0

Hz , 2H, Ar-H

6.6 ), 8.494, (d, ^Jhh=1-60 Hz 2H, Ar-H 3,3 ), 7.697, (dd, ^Jhh=6.00 Hz , V hh= 1-60
Hz, 2H, Ar-H 5,5'), 2.827, (q, J=7.60 Hz, 4H Ar-CHzCHg), 1.337, (t, J=7.60 Hz,
4H, Ar-CHzCHs);
NMR: ■'^C f H } (100 MHz, 298.1 K, DMSO-de) § 157.140 (2C, 2 ,2 ) 157.110
(2C, 4/4') 148.322 (2C, 6/6') 127.986 (2C, 3/3') 124.719 (2C, 5/5') 37.338 (2C,
Ar-CHzCHs) 23.147 (2C, Ar-CHzCHg)
Compound 4 is novel.
3.3.A. 4,4'-Bis[propyl]-2,2'-bipyridine, 5
MS (El: 70 eV, m/z) 241 (M ^\ 72.5%), 212 (M^ -CH 3 , 100%) 184 (M^ CH 2 CH 3 , 14.75%)
Compound 5 has previously been synthesized [64].
3.3.B. (4,4'-Bis[propyl]-2,2'-bipyridine) PtClz, 6
Analytical Calculated for CieHzoClzNzPt: C37.95 %, H 3.98 %, N 5.53 %.
Experimental: C 37.53 %, H3.98 %, N 5.53 %.
NMR: ^H (400 MHz, 298.1 K, DMSO-de) Ô 9.286, (d,
6.6 ), 8.491, (d,

^ J h h = 1 .6 0 2 H ,

Ar-H 3,3'), 7.682, (dd,

^ U h h = 6 .0 0

^ J h h = 6 .0 0

Hz

Hz , 2H, Ar-H
'^ J h h = 1 - 6 0
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Hz ,

2H, Ar-H 5,5'), 2.764 (t, J=7.Q0 Hz, 4H, Ar-CHgCHzCHa), 1.776, (m, 4H, ArCH 2 CH 2 CH 3 ), 0.972, (t, J=7.20 Hz,
NMR:

6

H, Ar-CH 2 CH 2 CH 3 )

{^H} (100 MHz, 298.1 K, DMSO-de) ô 157.140 (20, 2,2 ) 157.110

(20, 4/4 ) 148.322 (20, 6/6 ) 127.986 (20, 3/3 ) 124.719 (20, 5/5') 37.338 (20,
Ar-CHzCHzCHe) 23.147 (2
Oompound

6

0

, Ar-CHzCHzCHe) 14.151 (2

0

, Ar-OHzOHzCHe)

is novel.

3.4.A. 4,4'-Bis[n-butyl]-2,2'-bipyridine, 7
NMR: ^H (400 MHz, 298.1 K, ODOL3 ) Ô 8.55, (d, ^Jhh=4.80 Hz , 2H, Ar-H

6 ,6

),

8.23, (s, 2H, Ar-H 3,3 ), 7.14, (d, ^Jhh=5.20 Hz , 2H, Ar-H 5,5'), 2.66, (t, J=7.60
Hz, 4H, Ar-OHzOHzOHzOHe), 1.66, (m, 4H, Ar-OHzOHzOHzOHs), 1.36 (m, 4H, ArOH2 OH2 OH2 OH3 ), 0.94 (t, J=7.20 Hz,

6

H, Ar-OHzOHzOHzOHe);

MS (El: 70eV, m/z) 269 (M ^\ 60%), 226 (M'-OHzOHzOHe, 100%) 183 (M^OHzOHzOHe, 21%)
3.4.B. (4,4'-Bis[butyl]-2,2'-bipyridine) PtOlz,
NMR: ■'H (400 MHz, 298.1 K, DMSO-de)

8

8

9.266 (d, ^Jhh=6.00 Hz, 2H, Ar-H

6,6'), 8.486 (d, ^Jhh=1-20, 2H, Ar-H 3,3 ), 7.678 (dd, ^Jhh=6.40 Hz, % H = 2 .0 0 ,

2H, Ar-H 5,5'),), 2.786 (t, J=7.60 Hz, 4H, Ar-OHzOHzOHzOHe) 1.720 (m, 4H, ArOHzOHzOHzOHe), 1.398 (m, 4H, Ar-OHzOHzOHzOHe), 0.957 (t, J=7.20 Hz,

6

H,

Ar-OHzOHzOHzOHe);
NMR: ■'^O {^H} (100 MHz, 298.1 K, DMSO-de)
157.073.1

8

157.378 (20, 2/2 )

(20, 4/4') 148.308 (20, 6/6 ) 127.904 (20, 3/3') 124.704 (20, 5/5')

35.142 (20, Ar-CHzOHzOHzOHe) 31.980 (20, Ar-OHzCHzOHzOHe) 22.455 (20,
Ar-OHzOHzCHzOHe) 14.352 (20, Ar-OHzOHzOHzCHe);
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Compound 8 has been previously been synthesized [55]. However, this is the
first synthesis of this compound utilizing COD-PtClz.
3.5. (4,4'-Bis[methoxy]-2,2'-bipyridine) PtClz, 9
Analytical Calculated for CizHizClzNzOzPt: C 29.89% , H 2.51 %, N 5.81 %.
Experimental: 0 29.68 %, H 2.51 %, N 5.66 % .
NMR: ■'H (400 MHz, 298.1 K, DMSO-dg) Ô 9.068, (d, Vhh=6.80 Hz, 2H, Ar-H
6

,6 '), 8.129, (d, % H=2.80 2H, Ar-H 3,3 ), 7.360, (dd, ^Jhh=6.80 Hz,^Jhh=2.80

Hz, 2H, Ar-H 5,5 ), 4.021, (s,

6

H, Ar-OCHs);

NMR: ^^0 f H} (100 MHz, 298.1 K, DMSO-de) Ô 168.443 (20, 2,2 ) 158.584
(20, 4/4') 149.692 (20, 6/6') 113.468 (20, 3/3 ) 111.340 (20, 5/5') 57.875 (20,
Ar-OCHs)
Oompound 9 is novel.
3.6.A. 4,4'-Bis[n-butyl-4-methoxy]-2,2'-bipyridine, 10
Analytical Calculated for O1 8 H2 4 N2 O 2 : 0 71.97 %, H 8.05 %, N 9.33 %.
Experimental: 0 71.82 %, H 7.75 %, N 9.41 %.
NMR:

■'H

Hz, 2H, Ar-H
Hz,

2

(400 MHz, 298.1 K, acetone-dg)
6 ,6

8

8.52, (dd,

), 8.33, (s, 2H, Ar-H 3,3'), 7.21, (dd,

^ J h h = 4 .8 0 H z , ^ J h h = 0 .8 0

^ J h h = 4 .8 0 H z ,^ J h h = 2 .0 0

H, Ar-H 5,5'), 3.35, (t, J=6.40 Hz, 4H, Ar-OHzOHzOHzOOHs), 3.27, (s,

6

H,

Ar-OHzOHzOHzOO/^3 ). 2.73 (t J=8.00 Hz, 4H, ArOHz), 1.86 (m, 4H, ArOHzOHzOHzOOH 3):

NMR: ■'^0 {^H} (100 MHz, 298.1 K, acetone-dg) 8 156.3 (20, 2/2') 152.1 (20,
4/4') 149.3 (20, 6/6 ) 124.2 (20, 3/3 ) 120.9 (20, 5/5') 71.4 (20, Ar-
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CH2CH2CH2OCH3) 57.9 (2 C. Ar-CH 2 CH 2 CH 2

0

CH 3 ) 31.8 (2 C, Ar-

CH2CH2CH2OCH3) 30.5 (2 C, Ar-CHzCHzCHzOCHz):

MS (El: 70eV, m/z) 301 (M "\ 34%), 255 (M^-CHzOCHz, 64%), 242 (M^CH 2 CH 2 OCH 3 . 100%), 184 (M ^ CH 2 CH 2OCH 3 , 32.5%).
Compound 10 Is novel.
3.6.B. (4,4'-Bis[n-butyl-4-methoxy]-2,2'-bipyridine) PtClz, 11
Analytical Calculated for C 1 8 H2 4 C I 2 N2 O 2 Pt: C 38.17 %, H 4.27 %, N 4.95 %.
Experimental: C 38.24 %, H 4.05 %, N 5.12 %.
NMR:
6

(400 MHz, 298.1 K, DMSO- de) 8 9.307, (d

,6 '), 8.523, (d,

^ J h h = 1 -6 0 H z ,

^ J h h = 6 .4 0 H z ,

2H, Ar-H 3,3 ), 7.703, (dd,

2H, Ar-H

^ J h h = 6 . 0 0 H z , '‘ J h h = 1 . 6 0

Hz, 2H, Ar-H 5,5'), 3.400, (t, J=6.40 Hz, 4H, Ar-CHzCHzCHzOCHz), 3.37, (s,

6

H,

Ar-CHzCHzCHzOCHz), 2.828 (t J=7.60 Hz, 4H, Ar-CHz), 1.976 (m, 4H, ArCH 2 CH 2 CH 2 OCH 3 )
NMR: ^^0 {^H} (100 MHz, 298.1 K, DMSO-dg) 5 157.378 (20, 2/2 ) 157.073.1
(20, 4/4') 148.308 (20,

6

/ 6 ') 127.904 (20, 3/3') 124.704 (20, 5/5 ) 71.4 (20, Ar-

OH2 OH2 CH 2 OOH 3 ) 57.9 (20, Ar-0H20H20H2ÜCH3) 31.8 (20, ArCH2 OH2 OH 2 OOH 3 ) 30.5 (20, Ar-0H2CH20H200H3);
Oompound 11 is novel.
Note: Peaks appearing in ^H NMR spectra at 2.50 ppm belong to DMSO-de and
at 3.33 ppm belong to H2 O. Peaks appearing in ^^0 NMR spectra at 40 ppm
belong to DMSO-de. For GO/MS most of the parent peaks have a M‘' \ this is due
to sample overloading in the column, these compounds correspond correctly in
their breakage pattern to the compound characterized.
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CHAPTER 4

DISCUSSION
In this investigation six distinct compounds of the type [4,4'-bis(substituted)2,2'-bipyridine] PtClg were successfully synthesized, isolated, purified and
characterized. Four of these are novel compounds: 4, 6, 9 and 11, these have
not been previously reported in the literature. Compounds 2, 4, 6, 8 are part of a
homologous series of increasing number of methylene groups in an alkyl chain at
the 4,4' position. In this series [4,4'-bis(methyl)-2,2'-bipyridine] PtClz was
omitted due to the fact that it had previously been synthesized as well as
biologically tested [51]. Compounds 9 and 11 are part of an incomplete
homologous series of increasing number of methylene groups in an alkylmethoxy chain at the 4,4' position.
The purpose of this investigation was to synthesize compounds for the
purpose of cytotoxic assays, carried out by another team. Some preliminary
cytotoxic assay results will be discussed briefly, and they demonstrate the
therapeutic potential of the compounds synthesized by this project.
Table 1 presents a comparative analysis of ^H NMR chemical shifts (400
MHz, 298.1 K, DMSO-de) and how these chemical shifts are affected by the
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different substituents in the 4,4' position as well as their effect by the increasing
chain length size.

Compound

N M R 'H :

N M R 'H :

NMR^H:

NMR^H:

(ppm)

(ppm)

(ppm)

(ppm)

Ar-6,6'

Ar-5,5'

Ar-4,4'

Ar-3,3'

9.515

7.865

8.441

8.601

9.284

7.70

N/A

8.497

9.286

7.682

N/A

8.491

9.266

7.678

N/A

8.486

9.068

7.360

N/A

8.129

9.307

7.703

N/A

8.523

(2,2'-bipyridine) PtC^, 2
CAS# 13965-31-6
(4,4'-bis[ethyl]-2,2'-bipyridine)
PtCb, 4
Novel Compound

(4,4'-bis[propyl]-2,2'-bipyridine)
PtClz,

6

Novel Compound

(4,4'-bis[butyl]-2,2'-bipyridine)
PtClz,

8

CAS #728910-99-4
(4,4'-bis[methoxy]-2,2'-bipyridine)
PtClz, 9
Novel Compound

(4,4'-bis[n-butyl-4-methoxy]-2,2'bipyridine) PtClz, 11
Novel Compound

TABLE 1. Comparison of

NMR peak shifts in the aromatic region for 6

coordinated compounds.
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NMR Comparison between ligand and coordinated compounds show the
electron withdrawing effect of the Pt (II) on the bipyridine ring. The effect spans
approximately from 0.1 to 1.00 ppm of values shifted downfield. The most
affected positions in decreasing order are as follows: 6,6' with a difference of
0.928 ppm, 4,4' with a difference of 0.783, 5,5' with a difference of 0.741 and
3,3' with a difference of 0.105 ppm. See Table 2 below for actual values.

Compound

NMR^H:

N M R 'H :

N M R 'H :

N M R 'H :

(ppm)

(ppm)

(ppm)

(ppm)

Ar-6,6'

Ar-5,5'

A r-4,4'

Ar-3,3'

8.587

7.124

7.658

8.496

9.515

7.865

8.441

8.601

(2 ,2 -bipyridine)
CAS #366-18-7
(2 ,2 -bipyridine) PtC^,
CAS# 13965-31-6

2

TABLE 2. Comparison of the aromatic region of

NMR values for the ligand

and its corresponding coordinated compound.

Problems encountered in the synthesis of the ligand:
Having to substitute two identical positions in a molecule presented one of the
main obstacles in synthesis and purification of the ligand species. Generating a
dianion in the 4,4' (benzylic) position of a 4,4'-bis(methyl)-2,2'-bipyridine via LDA
is generally easy to achieve, as well as substituting that position with an alkyl
halide in an S n2 reaction. The problem arrives with not knowing exactly how
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much excess of base needs to be added considering the high reactivity of the
base toward trace amounts moisture present in the purging gas. Typically n-BuLi
reacts with water to form LiOH and release butane, in an acid-base reaction. The
reaction for the substitution of the ligand was carried under and inert gas, Na or
Ar. Even with precautions, there is always an amount of moisture in the system
causing the base to be consumed. Optimizations of a specific system must be
explored, until the excess has been optimized to yield substitutions at two
positions yielding one single disubstituted product. Very often these reactions
run even at 2.5 excess of base will yield two products a monosubstituted and
disubstituted (the desired product).
Print Daw: 19 M ar20 07 13:47:06

MS Data Review Active Chromatogram and Spectrum Plots • 3/19/2007 1:4? PM
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Figure 8a.
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Figure 8b.
Figure 8a-b. GC/MS for a synthesis of compound 3 utilizing 2.5 eq. of base.

On a few occasions, the system is all too efficient yielding two products as
well, a disubstituted and a trisubstituted product. This is demonstrated in a
synthesis of compound 3 where 2.5 equivalence of base was used. Figure 8a.
Illustrates the disubstituted product and Figure 6b shows the trisubstituted
product with the GC distribution as well as the MS break down. This can be
compared to the final synthesis of compound 3 where 2.2 eq. of base was used.
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thus yielding one product, the desired disubstituted. (See page 34 of Appendix
for GC/MS spectra of final compound 3).
Preliminary cytotoxicity:
S. Carper et al. (personal communication) have assessed preliminary results
of the cytotoxic activity of compounds

8

and

11

in various cancer cell lines

utilizing a clonogenic survival assay.

Cancer Cell
Line

Cancer Type

Cisplatin
(pM)

MDA-MB-435

Breast

320

1.4

4.8

MDA-MB-231

Breast

350

1.5

16

MCF-7

Breast

305

6.4

33.2

DC-4

Breast

5.01

1.9

1.9

DB-46

Breast

4.29

1.5

1 0 .2

DU-145

Prostate

490

2.5

2 2 .2

A-549

Lung

900

9

24.6

Compound
(pM)

Table 3. EC 5 0 comparison of cisplatin, compound

8

8

Compound 11
(pM)

and 11 in breast cancer.

These results are promising considering the range of activity is approx. 2.6 to
233.3 fold of cisplatin cytotoxicity, depending on the compound and cell line.
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CHAPTER 5

CONCLUSION
In this investigation successful synthesis of substituted ligands of the type
4,4'-bis(alkyl)-2,2'-bipyridines and their consequent coordination to Pt (II) was
achieved. Syntheses of six cisplatin-analogs were generated and four of these
compounds are novel. Two of these compounds, (4,4'-Bis[butyl]-2,2'-bipyridine)
PtCl2 , 8 and (4,4'-Bis[n-butyl-4-methoxy]-2,2'-bipyridine) PtCIa, 11, have been
preliminarily tested for their biological properties and their cytotoxic properties are
higher then cisplatin by 2.6 to 233.3 fold, depending on the compound and the
cell line. These numbers demonstrate the potential for treatment, however the
mechanism of these compounds is not know and assessments about their
behavior inside a body can not be properly made at this time.
Future prospects related to this investigation would yield a broader range of
coordinated compounds to Pt (II) with different functional group substituents in
the 4,4' position, such as hydroxyl, a series of increasing alkyl chains with
hydroxyl substituents, amine, aldehyde, carboxylic acid and various other
compounds.
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APPENDIX I

^H,

NMR AND GC/MS SPECTRA
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NMR of (2,2'-bipyridine) PtClz, 2
(400 MHz, 298.1 K, DMSO-de)
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NMR of (2,2'-bipyridine) PtCh, 2
(400 MHz, 298.1 K, DMSO-de)
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NMR of (2,2'-bipyhdine) PtCb, 2
(100 MHz, 298.1 K, DMSO-de)
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GC/MS of 4,4'-Bis[ethyl]-2,2'-bipyridine, 3
(CH 2 CI2 )
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NMR of (4.4'-Bis[ethyl]-2,2'-bipyridine) PtCl2 , 4
(400 MHz. 298.1 K, DMSO-de)

H ^ a o
O H p -x m M O -o »
rt
—
a. .a

< ^ o
z -•■o H » e
Z ^ n n o
—' I/) Ml
» n 'i3 -> iA
bib> 'O'O n o

r a* m
h» n . <*
ra C rtl« *o
a —
n 3 M.

0 CO ■ a <

7.697
7.693

2.808

2.511
— 2.502

1.331

43

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

>

STANDARD IH

OBSERVE -

p r o f ile

A u t o m a t i o n d i r e c t o r y : / h o m e / v b o d g e / v n m r s y s / d a t a / a u t o ^ Z B O ? . 0 3 . Z2_ 0 4
F i l e : / h o m e / v h o d g e / v n m r s y s / d a t a / Z E Y N E P / Z G K I 03 8 0 3 - 2 2 - 0 7 . f i d
S a m p le i d
s_20070322_01
S a m p l e : ZGK I 0 3 8 0 3 - 2 2 - 0 7
P u ls e

Sequence:

s2 pu1

S o l v e n t : d ms o
T em p. 2 5 . 0 C / 2 3 8 . 1
O p e r a t o r : vhodge
F ile :
VN MR S- 4Q0
"n*r400"

CNJ

9
CL

'Ô'
c

-a

I
10

CD

•o

K

R e la x , d e la y 1 .00 0 sec
P u lse 45.0 degrees
Acq. tim e 2 .0 4 9 sec
W i d t h 6 4 1 0 . 3 Hz
16 r e p e t i t i o n s
OBSERVE
H I, 399.7583921
DATA PROCESSING
L i n e b r o a d e n i n g 0 . 2 Hz
FT s i z e 6 5 53 6
T o t a l t i m e o m i n , 55 s e c

CO
(/)

CD
Q .

MHZ

6
CO

"O
CD

Û

C\J_

2

CnT

Q .

C

g

00

"G

03

3

"O

CM

œ
CO

Vi-

2
2

N

Q .

X

o
o

■c

‘o
0:

g
l->-

T
ppm

8
O
c
g

CO
( /)

CD
Q .

"O

8

"O
2

Q .
CD

q:

NMR of (4,4'-Bis[ethyl]-2,2'-bipyridine) PtCb, 4
(400 MHz, 298.1 K, DMSO-de)

if)

t) *□ <

o

11=1

I

MÏ

.1.33 7

45

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

NMRof(4,4'-Bis[ethyl]-2,2'-bipyridine) PtClz, 4
(100 MHz, 298.1 K, DMSO-de)
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GC/MS of 4 , 4 -Bis[propyl]-2,2 -bipyridine, 5
(CH 2 CI2 )
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NMR of (4,4'-Bis[propyl]-2,2'-bipyridine) PtC^, 6
(400 MHz, 298.1 K, DMSO-de)
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NMR of (4,4'-Bis[propyl]-2,2'-bipyridine) PtCIa, 6
(400 MHz, 298.1 K, DMSO-de)
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NMR of (4,4'-Bis[propyl]-2,2'-bipyridine) PtCIa, 6
(100 MHz, 298.1 K, DMSO-de)
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GC/MS of 4,4'-Bis[n-butyl]-2,2'-bipyridine, 7
(CH 2 CI2 )
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NMR of (4,4'-Bis[butyl]-2,2 '-bipyridine) PtClz, 8
(400 MHz, 298.1 K, DMSO-de)
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NMR of (4,4'-Bis[butyl]-2,2'-bipyridine) PtClz, 8
(400 MHz, 298.1 K, DMSO-de)
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NMR of (4,4'-Bis[butyl]-2,2'-bipyridine) PtCl2 , 8
(400 MHz, 298.1 K, DMSO-dg)
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NMR of (4,4'-Bis[butyl]-2,2'-bipyridine) PtCl2 , 8
(100 MHz, 298.1 K, DMSO-de)
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NMR of (4,4'-Bis[methoxy]-2,2'-bipyricline) PtCb, 9
(400 MHz, 298.1 K, DMSO-de)
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NMR of (4,4'-Bis[methoxy]-2,2'-bipyridine) PtC^, 9
(400 MHz, 298.1 K, DMSO-de)
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NMR of (4,4'-Bis[methoxy]-2,2'-bipyridine) PtCb, 9
(100 MHz, 298.1 K, DMSO-de)
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Q.o

GC/MS of 4,4'-Bis[n-butyl-4-methoxy]-2,2'-bipyridine, 10
(CH2CI2)
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NMR of (4,4'-Bis[n-butyl-4-methoxy]-2,2'-bipyricline) PtCb, 11
(400 MHz, 298.1 K, DMSO-de)
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NMR of (4,4'-Bis[n-butyl-4-methoxy]-2,2'-bipyridine) PtC^, 11
(400 MHz, 298.1 K, DMSO-de)
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NMR of (4,4'-Bis[n-butyl-4-methoxy]-2,2'-bipyridine) PtCb, 11
(400 MHz, 298.1 K, DMSO-de)
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NMR of (4,4'-Bis[n-butyl-4-methoxy]-2,2'-bipyridine) PtC^, 11
(100 MHz, 298.1 K, DMSO-de)
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